BSAM
ALDX icon

Blue Sky Asset Management’s Aldeyra Therapeutics ALDX Stock Holding History

Blue Sky Asset Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-16,710
Closed -$97K – 68
2019
Q4 		$97K Buy
+16,710
New +$96.5K 0.03% 102

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

Blue Sky Asset Management's ALDX Position: Q1 2020 in Review

Blue Sky Asset Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2020, closing a stake of 16,710 shares — an estimated $97K sold.

Blue Sky Asset Management first reported a position in ALDX in Q4 2019 and held it in 1 quarter. The position peaked at $97K in Q4 2019. 72 funds tracked by Wall St. Rank hold ALDX as of Q1 2020.

  • Blue Sky Asset Management reported no remaining Aldeyra Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Blue Sky Asset Management sold 16,710 Aldeyra Therapeutics shares in Q1 2020, an estimated $97K.
  • Blue Sky Asset Management first reported a position in Aldeyra Therapeutics in Q4 2019 and held it in 1 quarter.
  • Blue Sky Asset Management's Aldeyra Therapeutics position peaked at $97K in Q4 2019.
  • 72 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2020.

Based on Blue Sky Asset Management's 13F filing for Q1 2020, filed 5 May 2020.